Piper Jaffray analyst Edward Tenthoff lowered his price target for Zafgen to $5 from $6, s saying the company held a Type A meeting with the FDA to discuss the clinical hold on the IND for ZGN-1061. In a research note to investors, Tenthoff says Zafgen reported positive Phase II diabetes data showing statistically significant A1C reduction of 1.1% with weight loss of 5 lbs at Week 12 and said ZGN-1061 has not shown any thrombogenic events in the clinic, providing confidence that the FDA will ultimately lift the clinical hold. Tenthoff maintains an Overweight rating.